{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:11:29Z","timestamp":1750219889175,"version":"3.41.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.lrr.2025.100500","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T07:34:55Z","timestamp":1736840095000},"page":"100500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas"],"prefix":"10.1016","volume":"23","author":[{"given":"Gen","family":"Hasegawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8520-9142","authenticated-orcid":false,"given":"Noriharu","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimichi","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lrr.2025.100500_bib0001","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/bjh.12659","article-title":"Differences in incidence and trends of haematological malignancies in Japan and the United States","volume":"164","author":"Chihara","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.lrr.2025.100500_bib0002","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3324\/haematol.2017.186577","article-title":"The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project","volume":"103","author":"Bellei","year":"2018","journal-title":"Haematologica."},{"issue":"3","key":"10.1016\/j.lrr.2025.100500_bib0003","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","article-title":"Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate","volume":"16","author":"Okeley","year":"2010","journal-title":"Clin. Cancer Res. Offic. J. Am. Assoc. Cancer Res."},{"issue":"10168","key":"10.1016\/j.lrr.2025.100500_bib0004","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.lrr.2025.100500_bib0005","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2025.100500_bib0006","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.lrr.2025.100500_bib0007","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/10428194.2019.1654100","article-title":"Retreatment with brentuximab vedotin in patients with relapsed\/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study","volume":"61","author":"Fukuhara","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.lrr.2025.100500_bib0008","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann. Oncol. Offic. J. Eur. Soc. Med. Oncol."},{"issue":"6","key":"10.1016\/j.lrr.2025.100500_bib0009","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","article-title":"CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin","volume":"14","author":"Chen","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.lrr.2025.100500_bib0010","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1111\/bjh.19335","article-title":"Clonal haematopoiesis: a common progenitor for cytotoxic peripheral T-cell lymphoma and angioimmunoblastic T-cell lymphoma","volume":"204","author":"Vogelsberg","year":"2024","journal-title":"Br. J. Haematol."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T17:14:48Z","timestamp":1750180488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048925000020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":10,"alternative-id":["S2213048925000020"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100500","relation":{},"ISSN":["2213-0489"],"issn-type":[{"type":"print","value":"2213-0489"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retreatment with brentuximab vedotin for discordant peripheral T-cell lymphomas","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100500","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100500"}}